Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
Initiated the Industry’s First Allogeneic CAR T Phase 2 Trial ALPHA2 Trial, Evaluating ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Patients, is Designed to Leverage the Ease and Convenience of…
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
GMP Site Designed to Enable Potential Clinical and Commercial Production of AlloCAR T™ Products for Patients in Greater China , Taiwan , South Korea and Singapore SOUTH SAN FRANCISCO, Calif.…
Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif. , Oct. 26, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology…
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
New Survey Focused on Access Limitations of Approved Autologous CAR T Therapies Reveals Only 50% of Eligible Cancer Patients Receive Treatment Increased Patient Demand , Manufacturing Capacity and Time to…
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
ALPHA2 Trial, Evaluating ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Patients, is Designed to Leverage the Ease and Convenience of a Single Dose of ALLO-501A Protocol Supported by Clinical and…